Noel Warfel

EDUCATION

2004 James Madison University

• BSc., Department of Integrated Science and Technology

2004 Johns Hopkins University

• MSc., Zanvyl Kreiger School of Arts and Science

2011 University of California, San Diego

• PhD., Biomedical Sciences graduate program

PROFESSIONAL EXPERIENCE

2015 - present Research Assistant Professor, University of Arizona

• Department of Cellular and Molecular Medicine

2013 - 2015 Research Assistant Professor, Medical University of South Carolina

• Joint appointment in the Hollings Cancer Center and Department of Biochemistry and Molecular Biology

2011 - 2013 Postdoctoral Fellow, Penn State University, HMC Cancer Institute

• Mentor: Dr. Wafik El-Deiry

2006 - 2011 Graduate Student, University of California, San Diego

• Mentor: Dr. Alexandra C. Newton

2004 - 2006 Graduate Research Fellow, National Cancer Insititute

• Mentor: Dr. Phillip Dennis

FELLOWSHIPS/GRANTS

2017 American Lung Association Lung Cancer Discovery Award

2016 American Cancer Society Research Scholar Grant

2012 - 2014 Ruth L. Kirschstein National Research Service Award

• National Cancer Institute (1F32CA174138-01)

2009 - 2011 Predoctoral Traineeship Award

• DoD Breast Cancer Research Program (BC093021)

2009 Dissertation Award, CBCRP (Declined in favor of DoD award)

2006 - 2008 Pharmacology training grant, UCSD

• NIH (5 T32 GM07752-28)

2004 - 2006 Molecular Targets and Drug Discovery Fellowship

• Joint program - NIH/Johns Hopkins University

AWARDS/HONORS

2013 AACR-Aflac Scholar in Training Award, AACR Annual Meeting

2012 Roland K. Robins Pharmacology Dissertation Award for best thesis, UCSD

2011 AACR Scholar in Training Award, Targeting PI3K/mTOR Signalling in Cancer

2004 Honors senior project in the department of ISAT, James Madison University

ASSOCIATIONS/SOCIETY MEMBERSHIPS

2015 - present University of Arizona Cancer Biology GIDP

2008 - present American Association for Cancer Research

2002 - 2006 Golden Key International Honor Society

SUPERVISION OF STUDENTS (2015-2016)

Supervision of 3 undergraduate students: Alva Sainz (entered Yale graduate program in biology fall of 2016), Isabella Brody-Calixito, and Ian Burton.

Supervision of 1 MSc student: Ashley Suiter

Supervision of 1 PhD student: Andrea Casillas

SERVICE

2016 - present UA COM MMI interviewer

2012 - present Peer reviewer for Cancer Biology and Therapy and Oncotarget

2009 Reviewer for Journal of Experimental & Clinical Cancer Research

PRESENTATIONS

2017 Poster presentation at AACR Prostate Cancer Meeting

2017 Invited speaker at Purdue University MCMP seminar series

2016 Poster presentation at 2016 AACR Annual Meeting

2016 Utilizing PIM Kinase inhibitors to target Nrf2-driven cancers. Invited Speaker, Pharmacology seminar series, Univ. of Arizona

2015 Targeting PIM Kinases to Overcome hypoxia-mediated therapeutic resistance. Invited Speaker, Cancer Biology seminar series, Univ. of Arizona Cancer Center

2014 Poster presentation at the 2014 Hollings Cancer Center Prostate Cancer Research Retreat

2013 Poster presentation at the 2013 AACR Annual Meeting

2013 Poster presentation at the 11th PSU postdoctoral society annual event

2012 Poster presentation at the 2012 AACR Annual Meeting

2011 Poster presentation at AACR PI3K/mTOR Signaling in Cancer meeting

2010 Invited Speaker at UCSD Biomedical Sciences annual graduate retreat

2010 Poster presentation at Salk Institute meeting on Protein Phosphorylation and Cell Signaling

2010 Poster presentation at CSHL PTEN and Pathways Meeting

2009 Poster presentation at 2009 AACR Annual Meeting

2008 Poster presentation at Salk meeting on protein phosphorylation

2008 Poster presentation at Experimental Biology Annual Meeting

2007 Invited Speaker at UCSD Biomedical Sciences annual graduate retreat

2006 Poster presentation at AACR Annual Meeting

PEER REVIEWED PUBLICATIONS

1. N. A. Warfel, E. R. Lepper, C. Zhang, W. D. Figg, P. A. Dennis, Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res 12, 3502 (2006).
2. C. A. Granville, N. Warfel, J. Tsurutani, M. C. Hollander, M. Robertson, S. D. Fox, T. D. Veenstra, H. J. Issaq, R. I. Linnoila, P. A. Dennis, Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13, 2281 (2007).
3. J. J. Gills, S. S. Castillo, C. Zhang, P. A. Petukhov, R. M. Memmott, M. Hollingshead, N. Warfel, J. Han, A. P. Kozikowski, P. A. Dennis, Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms. J Biol Chem 282, 27020 (2007).
4. J. J. Gills, J. Lopiccolo, J. Tsurutani, R. H. Shoemaker, C. J. Best, M. S. Abu-Asab, J. Borojerdi, N. A. Warfel, E. R. Gardner, M. Danish, M. C. Hollander, S. Kawabata, M. Tsokos, W. D. Figg, P. S. Steeg, P. A. Dennis, Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13, 5183 (2007).
5. J. Brognard, M. Niederst, G. Reyes, N. Warfel, A. C. Newton, Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J Biol Chem 284, 15215 (2009).
6. N. A. Warfel, M. Niederst, M. W. Stevens, P. M. Brennan, M. C. Frame, A. C. Newton, Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem 286, 19777 (2011).
7. N. A. Warfel, M. Niederst, A. C. Newton, Disruption of the interface between the PH and kinase domains of Akt is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem, (2011).
8. N. A. Warfel, A. C. Newton, PH domain Leucine-rich Repeat Protein Phosphatase, PHLPP: a New Player in Cell Signaling. J Biol Chem, (2011).
9. V.V. Prabhu, N.A. Warfel, W.S. El-Deiry, CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle, (2012).
10. N. A. Warfel, W. S. El-Deiry, p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25, 52 (Jan, 2013).
11. N.A. Warfel, N. Dolloff, Dicker D.T., J. Malysz, W. S. El-Diery, CDK1-mediated phosphorylation of Ser668 stabalizes HIF-1a to promote tumor growth. Cell Cycle (2013).
12. N.A. Warfel and W.S. El-Deiry, HIF-1 Signaling in Drug Resistance to Chemotherapy. Curr Med Chem, (2014).
13. N.A. Warfel and A.S. Kraft, PIM Kinase (and Akt) Biology and Signaling in Tumors. Pharmacology and Therapeutics, (2015).
14. Zhang S., Zhou L., Hong B., van den Heuvel A.P., Prabhu V.V., Warfel N.A., Kline C.L., Dicker D.T., Kopelovich L., El-Deiry W.S. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer research, (2015)
15. Song J.H., Padi S.K., Luevano L.A., Minden M.D., DeAngelo D.J., Hardiman G., Ball L.E., Warfel N.A., Kraft A.S. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. (2016).
16. Warfel N.A*., Sainz A.G., Song J.H., Kraft A.S*. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Molecular Cancer Therapeutics. (2016). *co-corresponding authors.
17. Warfel N.A. Targeting CDK4/6 to Oppose Hypoxia-Mediated Therapeutic Resistance. Cell Cycle, (2017).
18. Casillas, A.L., Sainz, A.G., Toth, R.K., Singh, N., Desai, A., Kraft, A.S., and Warfel, N.A. Hypoxia-inducible PIM Kinase expression promotes resistance to anti-angiogenic agents. Clinical Cancer Research, (2018).